Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to BRAF-targeted therapy in melanoma.

European journal of cancer (Oxford, England : 1990) - 1 Apr 2013

Sullivan Ryan J, Flaherty Keith T

Abstract excerpt

BRAF mutations are identified in 40-50% of patients with melanoma. Treatment of these patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor trametinib is associated with improved clinical benefit (response rate, progression free survival, and overall survival)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Vemurafenib
Share to Pyrimidinones
Share to Sulfonamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Indoles

Share to MAP Kinase Signaling System

Share to Oximes

Share to Pyridones

Source

Identifiers

PMID: 23290787
DOI: 10.1016/j.ejca.2012.11.019

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23290787-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to BRAF-targeted therapy in melanoma.PMID 23290787Read ↗

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read ↗

Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.Semantic proximity Read ↗

[Mechanisms of resistance to anti-BRAF treatments].Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

Resistance to BRAF inhibition in melanomas.Semantic proximity Read ↗

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.